Entry Point Capital, LLC Viridian Therapeutics, Inc.\De Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Entry Point Capital, LLC holds 10,374 shares of VRDN stock, worth $298,148. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,374
Previous 13,232
21.6%
Holding current value
$298,148
Previous $184,000
21.2%
% of portfolio
0.09%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
81.6MCall Options Held
39.6KPut Options Held
94.3K-
Deep Track Capital, LP Greenwich, CT5.38MShares$155 Million3.65% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$137 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$127 Million8.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$125 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$112 Million12.69% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $1.15B
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...